BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11212427)

  • 1. Drug information needs clarification.
    Grossman LD
    Can Fam Physician; 2001 Jan; 47():28-30. PubMed ID: 11212427
    [No Abstract]   [Full Text] [Related]  

  • 2. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
    Martens MG
    J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene and its role in breast cancer prevention.
    Eng-Wong J; Zujewski JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of raloxifene in postmenopausal women.
    Cole RC; Flaws JA; Bush TL
    N Engl J Med; 1998 Apr; 338(18):1313; author reply 1313-4. PubMed ID: 9565492
    [No Abstract]   [Full Text] [Related]  

  • 8. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T; Mannella P; Genazzani AR
    Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene: new preparation. Not better than oestrogen.
    Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene: a new class of anti-estrogens for the prevention of osteoporosis.
    Kupecz D
    Nurse Pract; 1998 Sep; 23(9):91-3. PubMed ID: 9778672
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
    Reincke M
    MMW Fortschr Med; 2003 Feb; 145(9):29. PubMed ID: 12769132
    [No Abstract]   [Full Text] [Related]  

  • 14. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 15. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene for prevention of osteoporotic fractures.
    Diehr S; Mijal S; Nashelsky J
    Am Fam Physician; 2005 Jul; 72(1):132-4. PubMed ID: 16035693
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
    Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?
    Hathirat S; Evans MF
    Can Fam Physician; 2001 Oct; 47():1982-4. PubMed ID: 11723592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.